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Suppressor cell activity was determined in 14 patients 
with stage I melanoma, treated with or without adjuvant 
Bacillus Calmette-Guerin (BCG) immunotherapy, and in 
27 normal healthy volunteers. An in vitro test system 
was used in which peripheral blood mononuclear cells 
when sfimulated with concanavalin A (ConA) signifi-
cantly suppress proliferative responses of fresh autolo-
gous mononuclear cells. In addition, lymphocyte stimu-
lation capacity to optimal and suboptimal concentra-
tions of phytohemagglutinin (PHA) was determined in 
44 BCG treated or not BCG treated melanoma patients 
and in 40 normal individuals . 
ConA induced suppressor cell activity was signifi-
cantly (p < 0.02) impaired in BCG treated melanoma 
patients (21.3 ± 3.1% suppression) when compared to not 
BCG treated patients (39.8 ± 5.6%) or to normals (38.3 
± 9.3%). Lymphocyte stimulation capacity was de-
pressed in all melanoma patients when suboptimal con-
centrations of PHA were used but was found to be not 
significantly altered at optimal concentration of PHA. 
The present study reveals that BCG immunotherapy 
impairs ConA induced suppressor cell activity in mela-
noma patients but does not influence lymphocyte stim-
ulation capacity. 
A variety of s uppressor cell sys t em s regula t e virtua lJy a ll 
immunological processes [1]. In tumor b earing individua ls s up-
pressor cells a ppear to b e involved in the immunological e n-
ha ncem e n t of tumor growth [2-5]. 
B acillus Calmette -Guerin (BCG) is one of the mos t widely 
used biological a djuvants in the immunotherapy of maligna n-
cies a nd has been s hown to modify the immune responses [6]. 
Consequ e ntly, several s tudies ha ve been p erformed t o investi-
gat e t h e e ffect of B CG on s uppressor celJ a c tivity. 
In mice, B CG infection a ctivates n a tural supressor cells [7] 
a nd induces th e de ve lopme nt of macrophage -like s uppressor 
cells [8], cap a ble of inhibiting cytotoxic T cell gener a tio n [9]. 
The presen t s tudy was p erformed in order to investiga t e the 
influe nce of B e G on s uppressor celJ activity in m ela noma 
p a tie nts . W e h ave used a n in vitro t est system in which p eriph-
er a l blood mononuclear cells (MNC) when s timulated with 
concan a va lin A (ConA) suppress proliferative res ponses of fresh 
a u tologous respo nder MNC [10, ll]. 
In a ddition, ly mphocyte s timulation capacity was de termined 
in m ela noma patie nts , treated with or without BCG. 
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Abbreviatians: 
BCG: Bacillus Calmette-Guerin 
ConA: Concanavalin A 
MNC: Mononuclear Cells 
N M: Nodular Melanomas 
SSM: S uperficia l S preading Melanomas 
PHA: Phytohemagglu tinin 
MATERIALS AND METHODS 
Patien.ts 
A tota l of 1 J J individuals was in vest iga ted, 44 pa tients wi th ma ligna n t 
melanoma, 13 males and 31 females, mean (x ) age 50.48 ± 2.4 yr (± 
standard error of the mean, S EM) and 67 sex- and age- matched normal 
healthy volunteers. In all patients, the primm-y melanoma les ion was 
excised wi th a margin of at least 5 cm on either side, followed by 
selective regional lymphadenectomy. Histolagically, t he tumors were 
classified as nodular melanomas (N M; 29 patients ) and superficial 
spreading melanomas (SSM; 15 pa tients). The invasion of the tumors 
in to the dermis differed from level 3 to level 4 according to Clark et a l 
[12]. 
No microscopic evidence of metas tases was observed in the regional 
ly mph nodes and thus all the pa tients exhibi ted stage I of the disease. 
No further progression of melanoma was observed during the time th e 
study was performed. Four weeks after surgery 22 prospective ly ran -
domized patients (x age 48.9 ± 3.4 yr; 15 NM; 7 SSM) were started on 
a BCG immunotherapy (lmmuno BCG, In titute Pasteur, Paris, 
France). BCG was applied in tradermally in weekly intervals (dosage 4-
6 X 10" BCG). The remaining pa tients (8 males, J4 females; x age 52 
± 1.5 yr; 14 NM , 8 SSM) did not receive any adjuvant immuno- and/ or 
chemotherapy at all. 
The blaad samples far Iymphacy te stimulatian with phyta hemagglu-
tinin (PHA) were taken in the BCG trea ted pa tients 9.7 ± 1.5 mo after 
surgery and in the pa tients treated by surgical excision alone (without 
immunotherapy) 8.5 ± 1.2 1110 a fter operatian. 
S uppressor ce ll ac tivity of MN C was determined in 7 female pa tien ts 
out of each group. Blood samples were taken in the BCG-trea ted 
patients (x age 53.1 ± 6.5 yr; 3 NM, 4 SSM) 7.4 ± 1.4 mo a fter surgery 
and in the BCG un t reated patients (x age 48.8 ± 5.1 yr; 4 NM, 3 SSM ) 
12.4 ± 2.6 mo afte r operation. 
Suppressar Cell Assay 
Man.onucLear cells: Mononuclear cells (MNC) from heparinized 
periphera l blood of patients and controls were isola ted us ing FicoU 
H ypaque (Pharmacia, U ppsala, Sweden) density centrifugation method 
of Boyum [1.3]. Cells at the in terphase were harvested, washed and 
resuspended in medium HPMI 1640 (Flow Laboratories, Irvine, UK ), 
supplemented wi th JO% normal human serum of a single pool, used in 
a ll experiments. 
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Activa.tian af MNC with CanA (first culture): Patients and contro l 
MNC, I X LO';/ml HPMI 1640, can ta ining 10% pooled human AB -
serum, were cultmed for ::3 to 4 days (a) wi th 12, 5 Itg/ml of ConA 
(Pharmacia, Uppsala, Sweden) (=ConA-activated MNC) and (b) wi th-
out the addition of ConA (=cantrol ce lls) . 
Con A-activated and cantrol cells were treated subsequently for 30 
min with mitomycin C, 50 Jlg/ml (Kyawa Hakko Kogya Co, Ltd. , T okio, 
J apan), blocking fur ther CanA induced DNA synthesis as seen in the 
proliferation assay. Afterwards the cells were washed 2 times wi th 100 
mM (X methylglu coside in HPMI J640 to remove ConA, followed by 2 
washe in medium alone. 
A ssay ( 0.1' suppressor cell a.ctivity (.~ecand culture): ConA-stimulated 
ce lls and control ce lls (first cult.ure) were cul tured wi th fresh auto logou 
MNC (responder ce lls ), respectively. T hese autalogous ce lls were taken 
3 to 4 days after the first cul ture from the identical individua l. In thi 
second cul ture, 1 x 10" Con A prestimulated or control ce lls were 
cul tured again for 3 to 4 days with and wi thout ConA standard dose 1 
Itg/ ml in 0.2 ml in na t-botta med micro test pla tes. 
Thymidine incorporation was measured after terminal 8 hr pulse 
wit.h 5 /lCi/ ml of6-H" thymidine (2 Ci/mM; Amersham, UK). Cells were 
processed on a S karton cell harvest.er and incorporation of "H TdR was 
measured by a liquid scin t illation counter as described previously 
[141-
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Data are expressed as mean desintigrations per minu te (dpm) of t he 
m ean ± standard error of t he mean (SEM). Va lues of ~dpm were 
cal c ula ted by substracting dpm of unstimulated cul t ures from dpm of 
stirn ulated sultures. 
To s tandardize resu lts and permi t evaluation of t he degree of sup-
pression the following fo rmu la was used: 
1 - ~ dpm ConA 
percent (%) s uppression = x 100 ~ dpm contro l 
~ dpm ConA represents ~ dpm after t he addition of ConA activated 
MNC to the second cult ure and ~ dpm control stands for {!,. dpm after 
t h e a ddi t ion of con trol ce lls (incubated but not ConA activated MNC) 
to the second culture . 
Lymphocyte Stimlllation 
Lymphocyte stimulation was measured by a whole blood method 
[15] , a test system, exhibiting t he advantage of minimal blood req uire-
ment a nd minimal a lteration of ce lls by ma nipulation a nd isolation 
procedmes [15]. Purified phytohemagglu t inin (PH A) HA 16/ 17 (Well -
come Research Laboratories, Beckenham, UK) was used as mitoge n in 
optim a l (0, I mitogen units/ml) and suboptimal (0.005 mitogen uni ts/ 
m l ) concent rations. 
Statistics 
Statistica l ana lysis was performed using t he Studen t's I-test. The 
correlation coeffi cient (r) was determined by linear regression analysis 
using least sq ua res fit. 
RESULTS 
Suppressor Cells 
The suppressor ceil activ ity of ConA stimulated MNC (x = 
21.3 ± SEM 3.1% suppression) of patients with stage I mela-
non"la, treated by BCG immunotherapy was found to be signifi-
cantly (p < 0.02) lower than the suppressor ceil activi ty of 
ConA stimulated MNC (39.8 ± 5.6%) of patients with melanoma 
treated by surgery alone (Table I); suppressor cell activity was 
also found to be significantly (p < 0.05) decreased when com-
pared to the suppressor cell activi ty of ConA stimulated MNC 
(38.3 ± 9.3%) of 27 normal healthy volunteers (Fig 1). No 
s ignifIcant difference was observed between the mean percent-
T ABLE I. eon.A·indllced suppressor cell activity in B eG treated 
(1-7) and ill. BeG lIn/reated (8-14) melanoma patients 
Con A Hc l.ivat.ion of :'H TdR inco rporation in response to ConA 
PaL. # MNC in firsl cu i· 
l ure period a dpm % suppression 
3527 ± 157 
+ 2722 ± 105 23 
2 7404 ± 454 
+ 5902 ± 468 20 
3 10224 ± 249 
+ 7048 ± 578 31 
4 6028 ± 249 
+ 5348 ± 427 11 
5 10936 ± 868 
+ 7406 ± 871 32 
6 8323 ± 152 
+ 7294 ± 333 12 
7 3408 ± 232 
+ 2738 ± 381 20 
8 44701 ± 817 
+ 31009 ± 641 3 i 
9 7303 ± 385 
+ 5374 ± 428 26 
10 41240±2317 
+ 18513 ± 862 55 
1 1 7267 ± 547 
+ 5550 ± 492 24 
12 10304 ± 54 1 
+ 4536 ± 605 56 
13 6808 ± 313 
+ 4632 ± 437 32 
14 16307 ± 981 
+ 7287 ± 482 55 
age suppression of untreated patients with normals. In addition, 
no correlation was observed between the percentage suppres-
sion and (a) the age of the patients (BCG: correlation coefficient 
r = 0.11; non BCG: r = 0.03) (b) the time after operation (BCG: 
r = 0.52; non-BCG: r = 0, 12) and (c) the histopathological type 
of t he tumors, in both BCG and untreated melanoma patients. 
Lymphocyte Stimulation 
The log-transformed values of lymphocyte are shown in Fig 
2. Usi ng suboptimal concentrations of PHA (0.005 mitogen 
uni ts/ ml) a significantly lower r esponse was observed in BCG-
treated melanoma patients (geometric mean (gX) = 13 x 103 
dpm/ cul ture; p < 0.005) or melanoma patients, treated by 
surgery alone (gX = 20 X 10:1 dpm/culture; p < 0.05) when 
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FIG I. ConA- induced suppressor ce ll activi ty is significantly im-
pa ired in mela noma patients, treated with BeG immunotherapy when 
compared to BeG un treated mela noma patients or normal individuals. 
LYMPHO CY TE STIMULATION 








'0 10 ~ 
BCG NON NORMALS 
BCG 
MELANOMA 
FIC 2. Data represent the log. transformed mean of desin t igrations 
per minute (dpm) ± SEM. Lymphocyte stimulation is depressed in 
melanoma patients when suboptima l (0.005 mitogen units/ ml) concen-
trations of PHA are used (0), but is found to be normal at optimal (0.1 
mitogen unit/ ml) concen trations of PHA (~). 
504 PEHAMBERGER AND KNAPP Vol. 76, No.6 
TABLE II. Absolute and relative numbers of leukocytes, lymphocytes and monocytes in BeG treated and in BeG untreated melanoma 
patients" 
Patients n" Leuk ocytes 
BCG 22 6346 ± 322 
No-BeG 22 6290 ± 389 
Normal va lues 4000-
10000/ mm" 
" Data represent the mean ± standard error of the mean (SEM). 
/, n = number of patien ts. 
cant difference was observed between BCG treated and un-
treated patients at suboptimal concentrations of PHA. 
No significant difference was found in lymphocyte s timula-
t ion capacity in the 3 groups of individuals (g'X: BCG melanoma: 
80 x 10:1 dpm/culture, non BCG melanoma: 80 X 10" dpm/ 
culture, normals; 100 X lO"/cultul"e) when optimal concentra-
tions of PHA (0.1 mitogen units) were used. Absolute a nd 
relative numbers of leukocytes, lymphocytes a nd monocytes of 
BCG a nd not BCG treated patients were found to be wi thin the 
normal ra nge (Table II). 
DISCUSSION 
It seems to be ge nerally accepted that t umor patients exhibi t 
several defects of in vivo or in vitro immune reactions. Fre-
quently these defects are not as pronounced as in classical 
immunodeficiency states. Impaired lymphocyte stimulation ca-
pacity, e.g., is usually only detectable when suboptimal mitogen 
doses a re used [16]. This was also found in the present study. 
Lymphocyte stimulation capacity was not significantly different 
between normals, BCG-treated and BCG untreated mela noma 
patients, respectively, when optimal concentrations of PHA 
were used. Only at suboptimal concentrations of PHA, lympho-
cyte stimulation capacity was significantly depressed in BCG-
treated as well as BCG untreated melanoma patients, when 
compared to normals. However, no significant difference was 
observed between both groups of patients, investigated. These 
reslilts indicate that BCG immunotherapy does not significantly 
influence overall lymphocyte stimulation capacity. 
However, more recently test systems have been developed 
which permit a more detailed study of in vitro immuno-respon-
siveness. In tumor immunology increasing interest has focused 
on suppressor cell assays since there is suggestive evidence, that 
suppressor cells may undermine an effective antitumor immune 
response a nd may lead to immunological enhancem ent of tumor 
growth [2-4]. Suppressor cells have been shown to interfere 
with (tumor) ant igen specific killer T cells [17). Furthermore, 
studies in mice revealed that suppressor T cells may even 
influence the outcome of some forms of cancer [3, 18] or may 
promote the growth of uJtravioiet light induced t umors [19]. In 
human ca ncer patients increased suppressor cell activity was 
found in both, cells of the lymphocyte and monocyte population 
[3, 4]. Increased suppressor T cell activity has been described 
in progressive osteogenic sarcomas [17]; suppressive monocytes 
were found in patients with multiple myeloma [20], Hodgkin's 
disease [21] and lung cancer [22]. Impaired suppressor cell 
activity has mainly been observed in several inflammatory 
diseases, including lupus erythemathosus [23], juvenile rheu-
matoid arthritis [24] , inflammatory bowel disease [25] and 
inflammatory uveal diseases [26]. 
.In most of these studies the ConA induced suppressor cell 
assay system [10] has been employed. This system measures 
the suppressive effect of ConA preac tivated cells for prolifera-
tive response of autologous or homologous responder cells. It 
thus measures in vitro-induced and not spontaneous suppressor 
cell activity. The suppressor cells detectable in this system have 
been shown to be of lymphocyte origin [11, 23]. 
Using this system we found that ConA-induced suppressor 
cell activity was significantly impaired in BCG-treated mela-
noma patients when compared to BCG untreated patients and 
Lymphocy tes Monocy tes 
25G5 ± 19G (40 ± 1.8%) 165 ± 2.7 (3.4 ± 0.5%) 
22 1.5 ± 168 (35 ± I.G%) 146 ± 2.5 (2.4 ± 0.4 %) 
1500- (20-50%) 100- (2-10%) 
35OO/mm') 800/ mm" 
normals, respectively. No s ignificant diffe rence was obse rved in 
the suppressor cell activity between normaJs a nd BCG un-
treated mela noma patients. These results indicate that system-
ically applied BCG impairs ConA induca ble suppressor cell 
activity. 
Other authors have used assays which measure suppressor T 
cell function by the suppression of pokeweed mitogen induced 
immunoglobulin production as determined by radioimmunoas -
say [27], or the suppression of the development of plasma cells 
[28]. Our observations of decreased suppressor activity for 
ConA induced proliferation do not necessarily implicate a Cor-
relation wit h decreased suppressor cell activity for other T cell 
functions or for B cell diffe rentiation into plasma cells . 
The impai.red ConA-induced suppressor cell activ ity in BCG-
treated melanoma patients might be expla ined by BCG-induced 
inflammation. As mentioned above, impaired suppressor cell 
activity has mainly been observed in several inflammatory 
diseases [23-26]. However, it was only observed to be impa ired 
in the acute phase of the respective diseases, when the int1am-
matory processes were going on and was normal when the 
disease was clinically in remission. Thus, it has been postulated 
that inflammation per se results in impaired ConA-induced 
suppressor cell activity [25]. Possibly, BCG-induced inflam-
mation a lso impai.rs ConA inducable suppressor cell activity. 
Another explanation could be that BCG induces the devel-
opment of antilymphocyte antibodies, capable of inhibiting 
suppressor cell activity . Antibodies cyto toxic for lymphocytes 
in vitro have been described in more than 30 diso rders, includ-
ing collagene diseases, cancer, renal transplant recipients [29J 
a nd even in healthy persons after vaccination wi th bacterial 
a nd viral antigens [30]. Some anti-T cell antibodies have been 
shown to inhibit suppressor cell activity in patients with sys-
temic lupus erythematosus [23]. In mice, antisera against T 
cells were shown to abolish suppressor cell activi ty in vitro a nd 
to reduce growth of transpla ntable syngenic tumors in vivo 
[3]. Thus it might be t hat BCG vaccination a lso leads to t h e 
formation of suppressor T cell (precursor) antibodies and that 
the observed impaired ConA-induced suppressor cell activity in 
BCG-treated patients is due to the presence of BCG-induced 
anti-T cell a ntibodies. 
Furthermore, one cou ld speculate that BCG activates su p-
pressor cells already in vivo, a nd that these in vivo activated 
suppressor cells cannot be further stimulated by ConA in vitro. 
With regard to this speculation it is interesting to note t hat in 
mice systemically applied BCG has been shown to activate 
na tural [7] and macrophage-like [8, 9] suppressor cells in vivo. 
Since increased suppressor cell activity is proposed to en-
hance tumor growth [2-5] impaired suppressor cell activity 
should lead to an increased antitumor r esponse of the host. 
Employing the ConA system [10] we found an impa ired sup-
pressor cell activity in BCG-treated melanoma patients. It 
rema ins to be proven whether this in vitro phenomenon is 
indeed of relevance in vivo, since clinical studies have not 
uniformly demonstrated a substantial beneficial effect of BCG 
stimulation in melanoma patient survival [6]. 
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